PCSK9 and type 2 diabetes mellitus: Interestingly, recent studies have revealed the pleiotropic effects of PCSK9 inhibitors—a cardiovascular drug that regulates low-density lipoprotein cholesterol—on autoimmune diseases [59], as well as the impact of APOF on type 2 diabetes.